Top Stories

Opioid Case Spotlights Use of AI for Health-Care Fraud

A software developer’s scheme to rig alerts to doctors so they would write more opioid prescriptions shows that bringing artificial intelligence into health-care decision-making has opened up new possibilities for fraud.

Mallinckrodt Defends Acthar Price in Bid to Toss Latest Case

Mallinckrodt ARD LLC defended its decision to raise the price of the multiple sclerosis drug Acthar by a factor of 1,000, arguing in New Jersey federal court that the drug’s status as a “gold standard” treatment is “the obvious reason for that price.”

PFAS: The 'Forever Chemicals'

97% of Americans have a detectable amount of per- and polyfluoroalkyl substances, or PFAS, in their blood, but we don’t yet know all of their health effects. The EPA says more than 600 PFAS chemicals are in the marketplace in the U.S., and the OECD says there could be 5,000 types worldwide. States are racing to regulate PFAS, while the federal government lags.

Up Next:

Greta Thunberg on Climate Change

Infrastructure: The Hardest Easiest Problem

The Big Four Are a Looming Threat to Big Law

Podcasts

Colin Wilhelm on Infrastructure Funding on Bloomberg Radio

'Bridgegate' and Electors: SCOTUS Deep Dive

Patriotic Millionaires ‘Move Needle’ on Taxing Rich (Podcast)